Activity – Page 3

Recent Advances in AI & Multi-Omics for Translational Research

2 months ago talkbio0Tagged agentic AI, AI-driven, Biological Markers, Cancer Research, Discover, DNA Integration, drug response, Machine Learning, Multiomics, Precision Medicine, Prediction, Stratification, Study models, Translational Research, Biomedical

AI-driven multi-omics integration; translational research; precision medicine; biomarker discovery; patient stratification; machine learning; foundation models; agentic AI; cancer research; drug response prediction

ViVac Pharma Appoints Keren Leshem as CEO to Advance RNA-LNP Cancer Immunotherapy

2 months ago talkbio0Tagged Appointments, Biotechnology, CEO, Immunotherapy for cancer, Keren Leshem, Leadership, RNA-LNP, ViVac Pharma

ViVac Pharma; Keren Leshem; CEO appointment; RNA-LNP; cancer immunotherapy; leadership; biotechnology

Lunit and Labcorp Partner to Transform Tumor Microenvironment Analysis with AI-Powered Digital Pathology

2 months ago talkbio0Tagged Artificial Intelligence, Biological Markers, digital pathology, Discover, Labcorp, Lunit, MET exon 14 skipping mutation, Non-Small Cell Lung Carcinoma, precision oncology, spatial profiling, Tumor Microenvironment

Lunit; Labcorp; artificial intelligence; digital pathology; tumor microenvironment; spatial profiling; biomarker discovery; precision oncology; non-small cell lung cancer (NSCLC); MET exon 14 skipping mutation

Mikael Dolsten Withdraws Candidacy for Novo Nordisk Board; Bavarian Nordic Chairman Resigns

3 months ago talkbio0Tagged Bavarian Nordic, board of directors, board shake-up, chairman resignation, Danish pharma, Mikael Dolsten, Nordisk, personal reasons, Withdraw (activity)

Mikael Dolsten; Novo Nordisk; board of directors; withdrawal; personal reasons; Novo Nordisk Foundation; board shake-up; Danish pharma; Bavarian Nordic; chairman resignation

Major Leadership Changes and Fundraising in Biotech: Metagenomi CEO Exit, Workforce Cuts; Cogent Biosciences Raises Over $475M

3 months ago talkbio0Tagged bezuclastinib, Brian Thomas, CEO, Cogent Biosciences, Exit, Fund Raising, hemophilia A program, Irish (ethnic group), Jian, layoffs, Metagenomi, pipeline focus, Workforce

Metagenomi; CEO exit; Brian Thomas; Jian Irish; workforce cuts; biotech layoffs; Cogent Biosciences; fundraising; bezuclastinib; hemophilia A program; pipeline focus

Eisai Expands Leqembi Subcutaneous Label, Accelerates Early U.S. Launch Progress for Alzheimer’s Disease

3 months ago talkbio0Tagged Alzheimer 's disease, at-home injection, dosing, Eisai, expansion, Labels (device), Leqembi, Maintenance, sBLA, starting dose, status - In progress, Subcutaneous Autoinjector, supplemental biologics, United States Food and Drug Administration

Eisai; Leqembi; subcutaneous autoinjector; label expansion; Supplemental Biologics License Application (sBLA); FDA; maintenance dosing; starting dose; early Alzheimer’s disease; at-home injection; launch progress

Creative Biolabs Sets the Bar Higher in Human Antibody Discovery with Cutting-Edge Platforms

3 months ago talkbio0Tagged AI-driven, antibody libraries, Creative Biolabs, Discover, Drug Development, Generative AI, human antibody, platforms

Creative Biolabs; human antibody discovery; AI-driven platforms; generative AI; antibody libraries; drug development

Solventum Appoints Heather Knight as Chief Commercial Officer

3 months ago talkbio0Tagged Appointments, Chief Commercial Officer, Chris Barry, Dental Solutions, Global commercial operations, Health Information Systems, Heather Knight, Leadership, MedSurg, medtech, R&D, Solventum

Solventum; Heather Knight; Chief Commercial Officer; MedTech; Leadership appointment; Chris Barry; MedSurg; Dental Solutions; Health Information Systems; Global commercial operations; R&D

Epiminder Appoints Mark McLellan as Chief Financial Officer

3 months ago talkbio0Tagged Appointments, authorization, CFO, Epilepsy, Epiminder, healthcare finance, Mark McLellan, medical device company, Minder system, Preventive monitoring, United States Food and Drug Administration

Epiminder; Mark McLellan; CFO appointment; epilepsy monitoring; Minder system; FDA authorization; healthcare finance; medical device company

Inspira Technologies Appoints Former Johnson & Johnson Executive as VP of Global Sales

3 months ago talkbio0Tagged Appointments, Arginine Vasopressin-Neurophysin II Preproprotein, board of directors, commercialization, global sales, Health care facility, Inspira Technologies, Johnson & Johnson, Leadership, Mike Hershkovitz

Inspira Technologies; Mike Hershkovitz; Johnson & Johnson; VP of Global Sales; leadership appointment; healthcare; commercialization; board of directors